Searching for the primary metabolic alterations of polycystic ovary syndrome by application of the untargeted metabolomics approach.

[1]  Merin Rose Mathew,et al.  Polycystic ovary syndrome and iron overload: biochemical link and underlying mechanisms with potential novel therapeutic avenues , 2022, Bioscience reports.

[2]  B. Lu,et al.  Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics , 2022, Journal of Endocrinological Investigation.

[3]  Yonggang Zhang,et al.  Discovery of novel serum metabolic biomarkers in patients with polycystic ovarian syndrome and premature ovarian failure , 2021, Bioengineered.

[4]  J. Qiao,et al.  Metabolomics and correlation network analysis of follicular fluid reveals associations between L-tryptophan, L-tyrosine, and polycystic ovary syndrome. , 2020, Biomedical chromatography : BMC.

[5]  É. Hajduch,et al.  Sphingolipid Metabolism and Signaling in Skeletal Muscle: From Physiology to Physiopathology , 2020, Frontiers in Endocrinology.

[6]  G. Yurtdaş,et al.  A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota , 2019, Journal of the American College of Nutrition.

[7]  Jing Yang,et al.  The effect of glutamine on Dehydroepiandrosterone-induced polycystic ovary syndrome rats , 2020, Journal of Ovarian Research.

[8]  Weiqing Wang,et al.  Correlation between glucose metabolism and serum steroid hormones in patients with polycystic ovary syndrome , 2020, Clinical endocrinology.

[9]  M. Szczuko,et al.  The implications of vitamin content in the plasma in reference to the parameters of carbohydrate metabolism and hormone and lipid profiles in PCOS , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  Xinru Wang,et al.  Metabolic alterations associated with polycystic ovary syndrome: a UPLC Q-Exactive based metabolomic study. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[11]  L. Gachkar,et al.  Effects of L-carnitine on Polycystic Ovary Syndrome , 2019, JBRA assisted reproduction.

[12]  Chunshu Jia,et al.  Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry , 2019, Molecular reproduction and development.

[13]  D. Rachoń,et al.  Identification of the metabolic fingerprints in women with polycystic ovary syndrome using the multiplatform metabolomics technique , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  G. Hatch,et al.  The relationship between phospholipids and insulin resistance: From clinical to experimental studies , 2018, Journal of cellular and molecular medicine.

[15]  M. Murri,et al.  Gut Microbiota and the Polycystic Ovary Syndrome: Influence of Sex, Sex Hormones, and Obesity , 2018, The Journal of clinical endocrinology and metabolism.

[16]  H. Yin,et al.  Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production? , 2016, The Journal of clinical endocrinology and metabolism.

[17]  Y. Bao,et al.  Tryptophan Predicts the Risk for Future Type 2 Diabetes , 2016, PloS one.

[18]  Minghui Zhu,et al.  Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers , 2015, Oxidative medicine and cellular longevity.

[19]  Qifu Li,et al.  Serum metabolomics study of polycystic ovary syndrome based on UPLC-QTOF-MS coupled with a pattern recognition approach , 2015, Analytical and Bioanalytical Chemistry.

[20]  R. McPherson,et al.  Acylcarnitines: potential implications for skeletal muscle insulin resistance , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  S. Saso,et al.  Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. , 2014, European journal of obstetrics, gynecology, and reproductive biology.

[22]  M. Murri,et al.  Metabolomics in polycystic ovary syndrome. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[23]  M. Murri,et al.  Proteomic and metabolomic approaches to the study of polycystic ovary syndrome , 2013, Molecular and Cellular Endocrinology.

[24]  Y. Igarashi,et al.  Improved High-Fat Diet-Induced Glucose Intolerance by an Oral Administration of Phytosphingosine , 2013, Bioscience, biotechnology, and biochemistry.

[25]  C. Yang,et al.  Inhibitory effects of isoflavonoids on rat prostate testosterone 5α-reductase. , 2012, Journal of acupuncture and meridian studies.

[26]  E. Diamanti-Kandarakis,et al.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. , 2012, Endocrine reviews.

[27]  X. Correig,et al.  Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. , 2012, Clinical chemistry.

[28]  J. Qiao,et al.  Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. , 2012, Journal of proteome research.

[29]  J. Baillargeon,et al.  Insulin and hyperandrogenism in women with polycystic ovary syndrome , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  S. Rota,et al.  Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. , 2008, Human reproduction.

[31]  M. Harma,et al.  Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. , 2001, Clinical biochemistry.

[32]  A. Dunaif,et al.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. , 1997, Endocrine reviews.

[33]  M. Okuhara,et al.  Riboflavin, a testosterone 5 alpha-reductase inhibitor. , 1990, The Journal of antibiotics.